Beyond prostate-specific antigen: Utilizing novel strategies to screen men for prostate cancer

Current Opinion in Urology

Volumn 26, Issue 5, 2016, Pages 459-465

  Loeb, Stacy ^a,b   Lilja, Hans ^a,d,e   Vickers, Andrew ^c  

^a Department of Urology ^*  (United States)

^b NEW YORK UNIVERSITY   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e LUND UNIVERSITY   (Sweden)

Author keywords

4kScore; PCA3; phi; prostate cancer markers; PSA

Indexed keywords

ONCOPROTEIN; PCA3 PROTEIN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG; PROSTATE CANCER ANTIGEN 3, HUMAN; TUMOR ANTIGEN;

4KSCORE; CANCER SCREENING; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; FUSION GENE; HUMAN; MULTICENTER STUDY (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HEALTH INDEX; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; TMPRSS2 ERG FUSION GENE; URINALYSIS; MALE; MASS SCREENING; PROSTATE TUMOR; TRENDS; URINE;

ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; HUMANS; MALE; MASS SCREENING; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 84973390117     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0000000000000316     Document Type: Review

References (68)

1. Lilja H, Christensson A, Dahlen U, et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 1991; 37:1618-1625.
2. Lee R, Localio AR, Armstrong K, et al. A meta-analysis of the performance characteristics of the free prostate-specific antigen test. Urology 2006; 67:762-768.
3. National Comprehensive Cancer Network Guidelines: Prostate Cancer Early Detection 2016. http://www.nccn.org/professionals/physician-gls/pdf/pros tate-detection.pdf. [Accessed 14 March 2016]
4. Parekh DJ, Punnen S, Sjoberg DD, et al. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with highgrade prostate cancer. Eur Urol 2015; 68:464-470.
5. Vickers AJ, Cronin AM, Aus G, et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden. BMC Med 2008; 6:19.
6. Vickers A, Cronin A, Roobol M, et al. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol 2010; 28:2493-2498.
7. Vickers AJ, Cronin AM, Aus G, et al. Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden. Cancer 2010; 116:2612-2620.
8. Vickers AJ, Cronin AM, Roobol MJ, et al. A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Clin Cancer Res 2010; 16:3232-3239.
9. Gupta A, Roobol MJ, Savage CJ, et al. A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands. Br J Cancer 2010; 103:708-714.
10. Benchikh A, Savage C, Cronin A, et al. A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France. BMC Cancer 2010; 10:635.
11. Bryant RJ, Sjoberg DD, Vickers AJ, et al. Predicting high-grade cancer at tencore prostate biopsy using four kallikrein markers measured in blood in the ProtecT study. J Natl Cancer Inst 2015; 107.
12. Stattin P, Vickers AJ, Sjoberg DD, et al. Improving the specificity of screening for lethal prostate cancer using prostate-specific antigen and a panel of kallikrein markers: a nested case-control study. Eur Urol 2015; 68:207-213.
13. Konety B, Zappala SM, Parekh DJ, et al. The 4Kscore(R) test reduces prostate biopsy rates in community and academic urology practices. Rev Urol 2015; 17:231-240.
14. Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2] pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 2011; 185:1650-1655.
15. Loeb S, Sanda MG, Broyles DL, et al. The prostate health index selectively identifies clinically significant prostate cancer. J Urol 2015; 193:1163-1169.
16. de la Calle C, Patil D, Wei JT, et al. Multicenter evaluation of the prostate health index (PHI) for detection of aggressive prostate cancer in biopsy-naive men. J Urol 2015; 194:65-72.
17. Guazzoni G, Nava L, Lazzeri M, et al. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Eur Urol 2011; 60:214-222.
18. Lazzeri M, Haese A, de la Taille A, et al. Serum isoform [-2]proPSA derivates (%p2PSA and phi) significantly improves the prediction of prostate cancer at initial biopsy in a tPSA range 2-10 ng/ml. A multicentric European Study. Eur Urol 2013; 63:986-994.
19. Nordström T, Vickers A, Assel M, et al. Comparison Between the Fourkallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. Eur Urol 2015; 68:139-146.
20. Lughezzani G, Lazzeri M, Larcher A, et al. Development and internal validation of a Prostate Health Index based nomogram for predicting prostate cancer at extended biopsy. J Urol 2012; 188:1144-1150.
21. Lughezzani G, Lazzeri M, Haese A, et al. Multicenter European external validation of a prostate health index-based nomogram for predicting prostate cancer at extended biopsy. Eur Urol 2014; 66:906-912.
22. Foley RW, Gorman L, Sharifi N, et al. Improving multivariable prostate cancer risk assessment using the Prostate Health Index. BJU Int 2016; 117:409-417.
23. Roobol M, Salman J, Azevedo N. Abstract 857: The Rotterdam prostate cancer risk calculator: Improved prediction with more relevant prebiopsy information, now in the palm of your hand. Stockholm: Eur Assoc Urol; 2014.
24. Fossati N, Buffi NM, Haese A, et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer: results from a multicentric european prospective study. Eur Urol 2015; 68:132-138.
25. Cantiello F, Russo GI, Ferro M, et al. Prognostic accuracy of Prostate Health Index and urinary prostate cancer antigen 3 in predicting pathologic features after radical prostatectomy. Urol Oncol 2015; 33:163.e115-163.e123.
26. Cantiello F, Russo GI, Cicione A, et al. PHI and PCA3 improve the prognostic performance of PRIAS and Epstein criteria in predicting insignificant prostate cancer in men eligible for active surveillance. World J Urol 2016; 34:485-493.
27. Guazzoni G, Lazzeri M, Nava L, et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol 2012; 61:455-466.
28. Lughezzani G, Lazzeri M, Buffi NM, et al. Preoperative prostate health index is an independent predictor of early biochemical recurrence after radical prostatectomy: results from a prospective single-center study. Urol Oncol 2015; 33:337.
29. Loeb S, Bruinsma SM, Nicholson J, et al. Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification. Eur Urol 2015; 67:619-626.
30. Hirama H, Sugimoto M, Ito K, et al. The impact of baseline [-2]proPSArelated indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort. J Cancer Res Clin Oncol 2014; 140:257-263.
31. Tosoian JJ, Loeb S, Feng Z, et al. Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol 2012; 188:1131-1136.
32. Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostatespecific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59:5975-5979.
33. Marks LS, Fradet Y, Deras IL, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007; 69:532-535.
34. Haese A, de la Taille A, van Poppel H, et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008; 54:1081-1088.
35. Wei JT, Feng Z, Partin AW, et al. Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J Clin Oncol 2014; 32:4066-4072.
36. Tosoian JJ, Loeb S, Kettermann A, et al. Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol 2010; 183:534-538.
37. Hessels D, van Gils MP, van Hooij O, et al. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate 2010; 70:10-16.
38. Liss MA, Santos R, Osann K, et al. PCA3 molecular urine assay for prostate cancer: association with pathologic features and impact of collection protocols. World J Urol 2011; 29:683-688.
39. Seisen T, Roupret M, Brault D, et al. Accuracy of the prostate health index versus the urinary prostate cancer antigen 3 score to predict overall and significant prostate cancer at initial biopsy. Prostate 2015; 75:103-111.
40. Hansen J, Auprich M, Ahyai SA, et al. Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol 2013; 63:201-209.
41. Elshafei A, Chevli KK, Moussa AS, et al. PCA3-based nomogram for predicting prostate cancer and high grade cancer on initial transrectal guided biopsy. Prostate 2015; 75:1951-1957.
42. Tomlins SA, Day JR, Lonigro RJ, et al. Urine TMPRSS2:ERG plus PCA3 for individualized prostate cancer risk assessment. Eur Urol 2015. [Epub ahead of print]. doi: 10.1016/j.eururo.2015.04.039.
43. Zheng SL, Sun J, Wiklund F, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008; 358:910-919.
44. Vickers A, Lilja H, Scardino P. Five genetic variants associated with prostate cancer. N Engl J Med 2008; 358:2740.
45. Salinas CA, Koopmeiners JS, Kwon EM, et al. Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. Prostate 2009; 69:363-372.
46. Park JH, Wacholder S, Gail MH, et al. Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat Genet 2010; 42:570-575.
47. Gallagher DJ, Vijai J, Cronin AM, et al. Susceptibility loci associated with prostate cancer progression and mortality. Clin Cancer Res 2010; 16:2819-2832.
48. Klein RJ, Hallden C, Gupta A, et al. Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men. Eur Urol 2012; 61:471-477.
49. Thalmann GN. It is time to move on. Eur Urol 2012; 61:478-479.
50. Savblom C, Hallden C, Cronin AM, et al. Genetic variation in KLK2 and KLK3 is associated with concentrations of hK2 and PSA in serum and seminal plasma in young men. Clin Chem 2014; 60:490-499.
51. Gronberg H, Adolfsson J, Aly M, et al. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study. Lancet Oncol 2015; 16:1667-1676.
52. Alahari SV, Eastlack SC, Alahari SK. Role of long noncoding RNAs in neoplasia: special emphasis on prostate cancer. Int Rev Cell Mol Biol 2016; 324:229-254.
53. Beharry AA, Lacoste S, O'Connor TR, Kool ET. Fluorescence monitoring of the oxidative repair of DNA alkylation damage by ALKBH3, a prostate cancer marker. J Am Chem Soc 2016; 138:3647-3650.
54. Bertoli G, Cava C, Castiglioni I. MicroRNAs as biomarkers for diagnosis, prognosis and theranostics in prostate cancer. Int J Mol Sci 2016; 17:e421. doi: 10.3390/ijms17030421.
55. Koppers-Lalic D, Hackenberg M, Menezes R, et al. Noninvasive prostate cancer detection by measuring miRNA variants (isomiRs) in urine extracellular vesicles. Oncotarget 2016.
56. Gao R, Cheng Z, deMello AJ, Choo J. Wash-free magnetic immunoassay of the PSA cancer marker using SERS and droplet microfluidics. Lab on a Chip 2016; 16:1022-1029.
57. Malentacchi F, Vinci S, Melina AD, et al. Urinary carbonic anhydrase IX splicing messenger RNA variants in urogenital cancers. Urol Oncol 2016. [Epub ahead of print]. doi: 10.1016/j.urolonc.2016.02.017.
58. Kadimisetty K, Mosa IM, Malla S, et al. 3D-printed supercapacitor-powered electrochemiluminescent protein immunoarray. Biosens Bioelectron 2016; 77:188-193.
59. Leman ES, Cannon GW, Trock BJ, et al. EPCA-2: a highly specific serum marker for prostate cancer. Urology 2007; 69:714-720.
60. Brown D. New Prostate Cancer Test May Detect More Tumors. The Washington Post. 26 April 2007.
61. Szabo L. Test shows promise in detecting prostate cancer. USA Today. 26 April 2007.
62. Diamandis EP. Early prostate cancer antigen-2: a controversial prostate cancer biomarker? Clin Chem 2010; 56:542-544.
63. Sreekumar A, Poisson LM, Rajendiran TM, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009; 457:910-914.
64. Jentzmik F, Stephan C, Miller K, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010; 58:12-18.
65. Morgan R, Boxall A, Bhatt A, et al. Engrailed-2 (EN2): a tumor specific urinary biomarker for the early diagnosis of prostate cancer. Clin Cancer Res 2011; 17:1090-1098.
66. Pandha H, Sorensen KD, Orntoft TF, et al. Urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer. BJU Int 2012; 110:E287-E292.
67. Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005; 353:1224-1235.
68. McKiernan J, Donovan MJ, O'Neill V, et al. A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy. JAMA Oncol 2016. [Epub ahead of print]. doi: 10.1001/jamaoncol. 2016.0097.